Mast Therapeutics, Inc.
https://savarapharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Mast Therapeutics, Inc.
Poland’s Quiet Pivot From Generics To Innovative Treatments
Poland is slowly expanding beyond its position as a central European generics hub. More established companies are adding innovative medicine pipelines and a small number of biotechs are making international deals.
BIO Notebook: Califf On RWE, Industry Execs On Growing Therapeutic Areas, And More
Insights from Day Four of the BIO International Convention include FDA commissioner Califf on the state of real-world evidence and how it impacts IRA negotiations, Roche's interest in cardiovascular/metabolic assets, Merck's plans in immunology, and industry's rising interest in neuropsychiatry.
BIO Notebook: Califf On RWE, Industry Execs On Growing Therapeutic Areas, And More
Insights from Day Four of the BIO International Convention include FDA commissioner Califf on the state of real-world evidence and how it impacts IRA negotiations, Roche's interest in cardiovascular/metabolic assets, Merck's plans in immunology, and industry's rising interest in neuropsychiatry.
Finance Watch: Clinical-Stage Autoimmune Start-Ups Garner Big Investments
Private Company Edition: Attovia will advance two anti-IL-31 programs with its $105m in series B funding, while ImmuNext secured $575m in a Royalty Pharma deal for its Sanofi-partnered drug. Also, Bluejay and Aardvark raised $182m and $85m, respectively, in series C rounds.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
- Other Names / Subsidiaries
-
- Adventrx Pharmaceuticals, Inc.
- Aires Pharmaceuticals, Inc.
- SynthRx, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice